NCT00772473已完成不适用
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Clinvest
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Compare baseline levels of CGRP measured during a migraine free period to those during the 4 phases (prodrome, mild, mod., severe) of migraine.
研究概览
简要总结
To assess CGRP levels in saliva through the evolution of migraine.
详细描述
The release of CGRP is assumed to be initiated early in the migraine process and increases as the headache intensifies. Levels of CGRP will be measured during the premonitory, mild, moderate, and severe phases of a single migraine attack and compared to the baseline value determined when the subject was headache free. Understanding of the clinical evolution of migraine CGRP release may have significant implications in acute treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to read, understand, and sign the informed consent
- •Subject is between the ages of 18 and 65, either male or female
- •Negative pregnancy test for those of childbearing potential.
- •Adequate birth control as approved by the investigator if of childbearing potential
- •Subjects must fulfill criteria for IHS migraine (1.1 or 1.2) with a history of 1-6 migraines per month within the past 3 months and at least 15 headache free days though out the previous three month time period
排除标准
- •Pregnant or breast feeding
- •Presence of any condition or symptoms that would knowingly alter the content of the saliva
- •Presence of any medical disease or condition that would interfere with the conduct of the study
- •Current use of other medications that would be contraindicated in those patients that will take triptan medications for treatment of migraine symptoms, ie. MAO inhibitors, lithium, methyergonovine, methysergide, or ergotamine-containing products
- •Use of migraine preventive medications in the three months prior to screening
- •History of drug or alcohol abuse that would interfere with the study
- •Any pathology of the salivary glands such as sialadenitis (e.g., Sjorgen's syndrome, viral or bacterial sialadenitis, obstructive sialadentitis)
- •History of hypersensitivity or allergy to triptan medications
- •Presence of diabetes, salivary gland tumors, liver disease, alcoholism, and neuropathy
- •More than 15 days per month of headache within the past 3 months
- •Participation in another investigative drug study within the past 30 days
结局指标
主要结局
Compare baseline levels of CGRP measured during a migraine free period to those during the 4 phases (prodrome, mild, mod., severe) of migraine.
时间窗: baseline,prodrome, mild, mod., severe, 4 hrs. post dose
次要结局
- CGRP levels compared to no headache and as function of prodrome symptoms, prediction of mod/sev headache; compare prodrome symptoms to those reported at screening to pre-tx,tx,post tx.(screening, prodrome, pre-treatment, mild, moderate tosevere, post treatment)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of MigraineMigraineNCT05768828University Medicine Greifswald20
已完成
不适用
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.Familial Hemiplegic MigraineNCT00358839Danish Headache Center20
已完成
不适用
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine SubjectsMigraineNCT04473976IRCCS National Neurological Institute "C. Mondino" Foundation55
已完成
4 期
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of ActionChronic MigraineNCT04271202Beth Israel Deaconess Medical Center64
已完成
不适用
Amylin and CGRP Head to Head Provocation in Migraine Without Aura PatientsMigraine Without AuraNCT03598075Danish Headache Center36